The board of directors of the Consun Pharmaceutical Group Limited announced that the shareholders of the Company and potential investors that, based on the preliminary review on the unaudited consolidated management accounts of the Group for the year ended 31 December 2019 and the information currently available to the Board, it is expected that the profit attributable to equity shareholders of the Company for the year 2019 would record a decrease of approximately 70% to 80% as compared to that for the year ended 31 December 2018, mainly due to the decrease in sales revenue of the Yulin Pharmaceutical Segment and the recognition of impairment of goodwill relating thereto.